Shibeikang Biomedical

Company Profile

Employee Corner

Celebrating SBK’s New Chapter: Relocation & Renewed Vision

Through perseverance and innovation, we are shaping the future today!Since its founding, Chengdu Shibeikang Biomedical Technology Co., Ltd. has continuously adv...

SBK001 Receives Epidemic Response Research Funding from Chengdu Hi-Tech Zone

SBK’s independently developed Class 1 chemical novel drug, SBK001, has been selected for funding under the 2020 second batch of the Chengdu Hi-Tech Zone’s Mea...

Dr. Hu Zhuohan, Deputy Director of the Drug Metabolism Committee of the Chinese Pharmacological Soci...

At 9:30 AM>During the meeting, Dr. Cen provided an overview of SBK’s background, highlighted his own professional achievements, introduced the expert advisory ...

Secretary-General of the Chengdu Talent Development Association Visits SBK to Offer Guidance and Sup...

On May 29, 2020, at 10:00 AM, Ms. Peng Xiaoxiao, Secretary-General of the Chengdu Talent Development Association, visited SBK for a work-related meeting. Dr. Ce...

SBK’s Class 1 Chemical Novel Drug SBK002 Approved for Clinical Trials

Chengdu Shibeikang Biomedical Technology Co., Ltd. has recently received official approval from the National Medical Products Administration (NMPA) to initiate ...

上一页12...67891011下一页